查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957591

2026年全球胜肽和寡核苷酸CDMO市場報告

Peptide And Oligonucleotide CDMO Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，胜肽和寡核苷酸CDMO的市場規模迅速擴張。預計該市場規模將從2025年的24.2億美元成長到2026年的27億美元，複合年成長率（CAGR）為11.9%。過去幾年的成長主要歸因於胜肽類藥物的推廣應用、合成寡核苷酸複雜性的增加、製藥公司內部生產能力的局限性、監管合規要求的日益嚴格以及反義和肽類藥物的早期應用。

預計未來幾年胜肽和寡核苷酸CDMO市場將快速成長，到2030年將達到40.3億美元，複合年成長率（CAGR）為10.5%。預測期內的成長要素包括寡核苷酸治療產品線的擴展、對罕見疾病和癌症治療投資的增加、對快速臨床試驗材料生產的需求不斷成長、對專業CDMO夥伴關係的偏好日益增強以及固相合成技術的進步。預測期內的關鍵趨勢包括胜肽和寡核苷酸生產的外包增加、對符合CGMP規範的複雜分子生產的需求不斷成長、端到端開發和生產服務的增強、對高活性、高純度治療藥物的日益關注以及可擴展和靈活的生產平台的日益普及。

個人化醫療的日益普及預計將推動胜肽和寡核苷酸CDMO市場的成長。個人化醫療是一種根據個人特徵（例如遺傳因素、環境和生活方式）客製化醫療方案和治療方法的醫療策略。這一成長受到多種因素的驅動，包括基因組分析技術的進步、分子層面疾病路徑的闡明，以及針對每位患者獨特遺傳背景和健康記錄量身定做的精準有效治療方法的需求。胜肽和寡核苷酸的合約開發和生產機構（CDMO）在這一領域發揮著至關重要的作用，它們能夠開發出適合特定患者需求的客製化治療性胜肽和寡核苷酸。例如，總部位於英國的個人化醫療聯盟於2024年2月宣布，美國食品藥物管理局（FDA）藥物評估與研究中心（CDER）已核准16種用於治療罕見疾病患者的新型個人化療法。與 2022 年獲批的 6 個項目相比，這是一個顯著的成長。因此，個人化醫療的快速發展正在推動胜肽和寡核苷酸 CDMO 市場的擴張。

胜肽和寡核苷酸CDMO市場的主要企業正優先考慮策略合作夥伴關係，以拓展服務組合、提陞技術專長並擴大市場影響。胜肽開發和生產合作夥伴關係是指旨在開發和生產肽類治療藥物的組織間達成的合作協議。例如，2023年5月，總部位於美國的合約開發和生產組織（CDMO）PolyPeptide Group AG與德國生物技術公司Numaferm GmbH達成合作，共同開發和生產胜肽類藥物。此次合作充分利用了PolyPeptide的cGMP生產能力和市場覆蓋範圍，以及Numaferm的環保胜肽生產技術和生化平台技能。該合作的核心是共同開發有前景的候選胜肽，並致力於實現更永續肽類原料藥（API）生產。

目錄

第1章：執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球胜肽和寡核苷酸CDMO市場：吸引力評分和分析
  • 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 工業4.0和智慧製造
    • 數位化、雲端運算、巨量資料、網路安全
    • 人工智慧（AI）和自主人工智慧
    • 永續性、氣候技術、循環經濟
  • 主要趨勢
    • 胜肽和寡核苷酸生產外包增加
    • 對符合CGMP規範的複雜分子生產的需求日益成長
    • 擴展端到端開發和製造服務
    • 人們越來越關注高效高純度的治療藥物
    • 擴大具有擴充性和柔軟性的製造平台的應用範圍

第5章 終端用戶產業市場分析

  • 生物製藥公司
  • 製藥公司
  • 研究機構
  • 學術機構及政府機構
  • 處於臨床階段的生物技術公司

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球胜肽和寡核苷酸CDMO市場：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球胜肽和寡核苷酸CDMO市場規模、比較和成長率分析
  • 全球胜肽和烷基化合物開發與生產組織（CDMO）市場表現：規模和成長，2020-2025年
  • 全球胜肽和寡核苷酸CDMO市場預測：規模和成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 依產品
  • 胜肽、寡核苷酸
  • 按服務類型
  • 合約開發，契約製造
  • 透過使用
  • 治療藥物、研究應用、診斷試劑及其他用途
  • 最終用戶
  • 生物製藥公司、製藥公司、研究機構、學術和政府機構以及其他最終用戶
  • 按類型細分：胜肽
  • 藥物原料藥（原料藥）、胜肽類藥物、胜肽合成及生產服務
  • 按型別細分：寡核苷酸
  • 反義寡核苷酸、siRNA 和 mRNA 寡核苷酸、寡核苷酸合成和生產服務

第10章 區域與國別分析

  • 全球胜肽和寡核苷酸CDMO市場：按地區分類，歷史數據和預測，2020-2025年，2025-2030年預測，2035年預測
  • 全球胜肽和寡核苷酸CDMO市場：按國家/地區分類，歷史數據和預測數據（2020-2025年、2025-2030年預測、2035年預測）。

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 胜肽和寡核苷酸CDMO市場：競爭格局和市場佔有率，2024年
  • 胜肽和寡核苷酸CDMO市場：公司估值矩陣
  • 胜肽和寡核苷酸CDMO市場：公司概況
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Ajinomoto Co. Inc.
    • Lonza Group AG
    • WuXi AppTec Co. Ltd.

第37章 其他大型企業和創新企業

  • Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA, CordenPharma International, Bachem Holding AG, GenScript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, AmbioPharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年胜肽和寡核苷酸CDMO市場：提供新機會的國家
  • 2030年胜肽和寡核苷酸CDMO市場：提供新機會的細分市場
  • 胜肽和寡核苷酸CDMO市場2030：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第41章附錄

簡介目錄
Product Code: PH3MPOCL01_G26Q1

A peptide and oligonucleotide CDMO (contract development and manufacturing organization) is a company offering services for the development, manufacturing, and supply of peptide- and oligonucleotide-based therapeutics. These organizations deliver specialized knowledge in synthetic chemistry, process development, analytical testing, and cGMP manufacturing to enable production of peptides and oligonucleotides for diverse clients.

The primary product categories for peptide and oligonucleotide CDMOs consist of peptides and oligonucleotides. Peptides are brief sequences of amino acids, generally under 50 in length, which serve key functions in biological activities like signaling and hormone control. They offer services including contract development and contract manufacturing. These find use in areas such as therapeutics, research tools, diagnostics, and more, serving end-users like biopharmaceutical firms, pharmaceutical companies, research institutions, academic and government bodies, and others.

Tariffs have affected the peptide and oligonucleotide CDMO market by increasing costs for imported raw materials, reagents, synthesis equipment, and specialized consumables used in manufacturing. These impacts are most pronounced in contract manufacturing services and therapeutic applications, particularly in regions dependent on cross-border chemical supply chains such as North America and Europe. Higher costs have pressured pricing and extended development timelines. However, tariffs have also encouraged localization of manufacturing, supplier diversification, and investments in domestic production capabilities.

The peptide and oligonucleotide cdmo market research report is one of a series of new reports from The Business Research Company that provides peptide and oligonucleotide cdmo market statistics, including peptide and oligonucleotide cdmo industry global market size, regional shares, competitors with a peptide and oligonucleotide cdmo market share, detailed peptide and oligonucleotide cdmo market segments, market trends and opportunities, and any further data you may need to thrive in the peptide and oligonucleotide cdmo industry. This peptide and oligonucleotide cdmo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide and oligonucleotide cdmo market size has grown rapidly in recent years. It will grow from $2.42 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to growth in peptide-based therapeutics, increasing complexity of synthetic oligonucleotides, limited in-house manufacturing capabilities of drug developers, rising regulatory compliance requirements, early adoption of antisense and peptide drugs.

The peptide and oligonucleotide cdmo market size is expected to see rapid growth in the next few years. It will grow to $4.03 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to expansion of oligonucleotide therapeutics pipelines, increasing investment in rare disease and oncology drugs, rising demand for rapid clinical trial material production, growing preference for specialized cdmo partnerships, advancements in solid-phase synthesis technologies. Major trends in the forecast period include rising outsourcing of peptide and oligonucleotide manufacturing, growing demand for cgmp-compliant complex molecule production, expansion of end-to-end development and manufacturing services, increased focus on high-potency and high-purity therapeutics, greater adoption of scalable and flexible manufacturing platforms.

The increasing uptake of personalized medicine is anticipated to fuel expansion in the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine represents a healthcare strategy that customizes medical choices and therapies based on individual factors like genetics, environment, and lifestyle. This rising adoption stems from various drivers, including progress in genomic tools, deeper insights into molecular disease pathways, and the need for precise, effective treatments matched to patients' unique genetic backgrounds and health records. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital in this field, as they create bespoke therapeutic peptides and oligonucleotides suited to specific patient requirements. For example, in February 2024, the Personalized Medicine Coalition-a UK organization advocating for personalized medicine-noted that the FDA's Center for Drug Evaluation and Research (CDER) greenlit 16 new personalized therapies for rare disease patients, compared to just 6 in 2022. Thus, the surge in personalized medicine is propelling the peptide and oligonucleotide CDMO market.

Major companies in the peptide and oligonucleotide CDMO market are prioritizing strategic partnerships to improve their service portfolios, bolster technological expertise, and broaden market presence. Peptide development and production partnerships involve collaborative deals between organizations aimed at creating and producing peptide-based therapies. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), teamed up with Numaferm GmbH, a Germany-based biotech firm, for peptide development and production. This alliance leverages PolyPeptide's cGMP manufacturing capabilities and market reach alongside Numaferm's skills in eco-friendly peptide manufacturing and biochemical platforms. The collaboration centers on co-developing promising peptide candidates to enable more sustainable production of peptide-based APIs.

In May 2024, EUROAPI, a France-based contract development and manufacturing organization, acquired BianoGMP for an undisclosed sum. The deal aimed to strengthen EUROAPI's standing in the contract development and manufacturing organization (CDMO) market for oligonucleotides, building on its existing capacity in Frankfurt. BianoGMP, a Germany-based contract development and manufacturing organization (CDMO), specializes in analytical services for oligonucleotides.

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide and oligonucleotide cdmo market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide and oligonucleotide CDMO market consists of revenues earned by entities by providing services such as analytical testing, oligonucleotide synthesis services, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. The peptide and oligonucleotide CDMO market also includes sales of custom peptides and custom oligonucleotides. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide And Oligonucleotide CDMO Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses peptide and oligonucleotide cdmo market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide and oligonucleotide cdmo ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peptide and oligonucleotide cdmo market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Product: Peptides; Oligonucleotides
  • 2) By Service Type: Contract Development; Contract Manufacturing;
  • 3) By Application: Therapeutics; Research Applications; Diagnostics; Other Applications
  • 4) By End User: Biopharmaceutical Companies; Pharmaceutical Companies; Research Institutes; Academic and Government Organizations; Other End Users
  • Subsegments:
  • 1) By Peptides: Active Pharmaceutical Ingredients (Apis); Peptide Drug Products; Peptide Synthesis And Manufacturing Services
  • 2) By Oligonucleotides: Antisense Oligonucleotides; Sirna And Mrna Oligonucleotides; Oligonucleotide Synthesis And Manufacturing Services
  • Companies Mentioned: Thermo Fisher Scientific Inc.; Merck KGaA; Ajinomoto Co. Inc.; Lonza Group Ag; Wuxi Apptec Co. Ltd.; Catalent Inc.; Piramal Pharma Ltd; Curia Global Inc.; Almac Group; Euroapi SA.; CordenPharma International; Bachem Holding AG; Genscript Biotech Corporation; PolyPeptide Group; Rentschler Biopharma SE; Ambiopharm Inc; ScinoPharm; Senn Chemicals AG; Aurigene Pharmaceutical Services; Creative Peptides; Sylentis S.A.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Peptide And Oligonucleotide CDMO Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Peptide And Oligonucleotide CDMO Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Peptide And Oligonucleotide CDMO Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Peptide And Oligonucleotide CDMO Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Industry 4.0 & Intelligent Manufacturing
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Artificial Intelligence & Autonomous Intelligence
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Rising Outsourcing Of Peptide And Oligonucleotide Manufacturing
    • 4.2.2 Growing Demand For Cgmp-Compliant Complex Molecule Production
    • 4.2.3 Expansion Of End-To-End Development And Manufacturing Services
    • 4.2.4 Increased Focus On High-Potency And High-Purity Therapeutics
    • 4.2.5 Greater Adoption Of Scalable And Flexible Manufacturing Platforms

5. Peptide And Oligonucleotide CDMO Market Analysis Of End Use Industries

  • 5.1 Biopharmaceutical Companies
  • 5.2 Pharmaceutical Companies
  • 5.3 Research Institutes
  • 5.4 Academic And Government Organizations
  • 5.5 Clinical-Stage Biotechnology Companies

6. Peptide And Oligonucleotide CDMO Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Peptide And Oligonucleotide CDMO Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Peptide And Oligonucleotide CDMO PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Peptide And Oligonucleotide CDMO Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Peptide And Oligonucleotide CDMO Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Peptide And Oligonucleotide CDMO Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Peptide And Oligonucleotide CDMO Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Peptide And Oligonucleotide CDMO Market Segmentation

  • 9.1. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Peptides, Oligonucleotides
  • 9.2. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Service Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Contract Development, Contract Manufacturing
  • 9.3. Global Peptide And Oligonucleotide CDMO Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Therapeutics, Research Applications, Diagnostics, Other Applications
  • 9.4. Global Peptide And Oligonucleotide CDMO Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users
  • 9.5. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Peptides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
  • 9.6. Global Peptide And Oligonucleotide CDMO Market, Sub-Segmentation Of Oligonucleotides, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

10. Peptide And Oligonucleotide CDMO Market Regional And Country Analysis

  • 10.1. Global Peptide And Oligonucleotide CDMO Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Peptide And Oligonucleotide CDMO Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Peptide And Oligonucleotide CDMO Market

  • 11.1. Asia-Pacific Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Peptide And Oligonucleotide CDMO Market

  • 12.1. China Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Peptide And Oligonucleotide CDMO Market

  • 13.1. India Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Peptide And Oligonucleotide CDMO Market

  • 14.1. Japan Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Peptide And Oligonucleotide CDMO Market

  • 15.1. Australia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Peptide And Oligonucleotide CDMO Market

  • 16.1. Indonesia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Peptide And Oligonucleotide CDMO Market

  • 17.1. South Korea Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Peptide And Oligonucleotide CDMO Market

  • 18.1. Taiwan Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Peptide And Oligonucleotide CDMO Market

  • 19.1. South East Asia Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Peptide And Oligonucleotide CDMO Market

  • 20.1. Western Europe Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Peptide And Oligonucleotide CDMO Market

  • 21.1. UK Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Peptide And Oligonucleotide CDMO Market

  • 22.1. Germany Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Peptide And Oligonucleotide CDMO Market

  • 23.1. France Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Peptide And Oligonucleotide CDMO Market

  • 24.1. Italy Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Peptide And Oligonucleotide CDMO Market

  • 25.1. Spain Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Peptide And Oligonucleotide CDMO Market

  • 26.1. Eastern Europe Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Peptide And Oligonucleotide CDMO Market

  • 27.1. Russia Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Peptide And Oligonucleotide CDMO Market

  • 28.1. North America Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Peptide And Oligonucleotide CDMO Market

  • 29.1. USA Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Peptide And Oligonucleotide CDMO Market

  • 30.1. Canada Peptide And Oligonucleotide CDMO Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Peptide And Oligonucleotide CDMO Market

  • 31.1. South America Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Peptide And Oligonucleotide CDMO Market

  • 32.1. Brazil Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Peptide And Oligonucleotide CDMO Market

  • 33.1. Middle East Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Peptide And Oligonucleotide CDMO Market

  • 34.1. Africa Peptide And Oligonucleotide CDMO Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Peptide And Oligonucleotide CDMO Market, Segmentation By Product, Segmentation By Service Type, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Peptide And Oligonucleotide CDMO Market Regulatory and Investment Landscape

36. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Company Profiles

  • 36.1. Peptide And Oligonucleotide CDMO Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Peptide And Oligonucleotide CDMO Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Peptide And Oligonucleotide CDMO Market Company Profiles
    • 36.3.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Ajinomoto Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Lonza Group AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. WuXi AppTec Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Peptide And Oligonucleotide CDMO Market Other Major And Innovative Companies

  • Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA, CordenPharma International, Bachem Holding AG, GenScript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, AmbioPharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides

38. Global Peptide And Oligonucleotide CDMO Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Peptide And Oligonucleotide CDMO Market

40. Peptide And Oligonucleotide CDMO Market High Potential Countries, Segments and Strategies

  • 40.1 Peptide And Oligonucleotide CDMO Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Peptide And Oligonucleotide CDMO Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Peptide And Oligonucleotide CDMO Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer